Ashwagandha Safety Pregnancy Lactation Research

Last updated: October 4, 2026 - Reviewed by Verdant Wellness Editorial Team

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before using any supplement, especially during pregnancy or breastfeeding.

Table of Contents

1. Why This Question Matters Right Now
2. What Is Ashwagandha and Why Do Pregnant Women Consider It?
3. Ashwagandha Pregnancy Safety: What the Evidence Actually Shows
4. The 2026 Human Clinical Study: A Closer Look
5. Risk Concerns: Miscarriage, Premature Delivery, and Fetal Harm
6. Ashwagandha Lactation: Is It Safe While Breastfeeding?
7. Ashwagandha Contraindications Beyond Pregnancy
8. Ashwagandha Drug Interactions You Need to Know
9. Ashwagandha Thyroid Interaction: Special Considerations
10. Ashwagandha Autoimmune Caution
11. Who Should Not Take Ashwagandha?
12. What Regulators Say: A Global Ashwagandha Safety Review
13. Ashwagandha Safety Cautions: Practical Summary for Readers
14. Frequently Asked Questions
15. Bottom Line

1. Why This Question Matters Right Now

Ashwagandha (Withania somnifera) has exploded in popularity over the past decade. Google Trends data consistently shows surging interest in adaptogenic herbs, and ashwagandha sits near the top of almost every "best stress supplements" list published between 2022 and 2026. Walk into any health food store or scroll through any wellness influencer's feed, and you'll find ashwagandha gummies, tinctures, capsules, and powders marketed for stress relief, energy, hormonal balance, and sleep — all concerns that are extraordinarily common during pregnancy and the postpartum period.

That marketing overlap creates a genuinely important public health question: Is ashwagandha safety in pregnancy and lactation supported by research, or is the supplement being consumed by a vulnerable population without adequate evidence?

The honest answer, as you'll discover throughout this post, is complicated. It is not a simple "yes, it's safe" or "no, it's dangerous." The picture in 2026 looks meaningfully different from 2020, thanks to new human clinical data and updated animal reproductive toxicity studies — but critical evidence gaps remain, and several major regulatory bodies continue to advise against use during pregnancy and breastfeeding.

This article synthesizes the most current peer-reviewed research, regulatory assessments, and clinical guidance to give you the most complete, honest picture available. Whether you are a pregnant woman weighing your options, a healthcare provider counseling patients, or simply a curious reader, you deserve evidence — not marketing copy.

★★★★★ 4.8 · 1,247 reviews

Feel Calm By Bedtime. Focused By Morning.

Adaptogen-based formula. Third-party tested. Made in an FDA-registered facility. Backed by a 60-day money-back guarantee.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

2. What Is Ashwagandha and Why Do Pregnant Women Consider It?

The Herb Itself

Ashwagandha is a small, woody shrub native to India, North Africa, and the Mediterranean region. Its roots and berries have been used in Ayurvedic medicine for over 3,000 years, primarily as a rasayana — a rejuvenating tonic believed to promote longevity, vitality, and resilience. The plant belongs to the nightshade family (Solanaceae) and contains a complex matrix of bioactive compounds, most notably withanolides, alkaloids (including somnine, somniferine, and withanine), saponins, and iron.

Modern research has focused heavily on the standardized root extract, particularly formulations standardized to a defined withanolide content (commonly 2.5–5% withanolides). This standardization matters enormously for research interpretation: a study using a standardized root extract cannot be automatically extrapolated to the raw root powder, berry extract, or leaf preparations commonly sold in stores.

Why Pregnant and Postpartum Women Are Drawn to It

Pregnancy and the postpartum period bring a predictable cluster of symptoms and concerns that map almost perfectly onto ashwagandha's marketed benefits:

• Chronic stress and anxiety — among the most commonly reported pregnancy complaints
• Sleep disturbance — affects the majority of pregnant women, especially in the third trimester
• Fatigue and low energy — nearly universal in the first trimester and late pregnancy
• Anemia and low hemoglobin — a significant maternal health concern, particularly in certain populations
• Hormonal fluctuation — postpartum thyroid dysregulation is relatively common

When a supplement is widely marketed as addressing all of these issues simultaneously — and when it carries the halo of "natural" and "ancient wisdom" — it is not surprising that pregnant and breastfeeding women reach for it. Understanding the full ashwagandha pregnancy safety picture is therefore not an academic exercise; it has real clinical relevance.

3. Ashwagandha Pregnancy Safety: What the Evidence Actually Shows

The Central Challenge: Evidence Quality

The question "is ashwagandha safe pregnant?" does not yet have a definitive, evidence-based answer — and understanding why that gap exists is the first step toward making an informed decision.

As of 2026, the evidence base for ashwagandha use in pregnancy consists of:

• One prospective randomized open-label human clinical trial in pregnant women (published 2026, n=70)
• Multiple animal reproductive and developmental toxicity studies, including a 2025 rat study
• Traditional use documentation from Ayurvedic texts and ethnobotanical literature
• Case reports, adverse event registries, and pharmacovigilance data of variable quality
• Regulatory risk assessments from agencies including Germany's Federal Institute for Risk Assessment (BfR) and reviews published through academic consensus platforms

The Consensus.app summary of existing literature states plainly that there is a lack of large-scale, well-designed randomized, double-blind, placebo-controlled trials in pregnant women, and warns of possible miscarriage, premature delivery, and fetal harm concerns based on traditional use records and pharmacological plausibility arguments.

This is not unusual for herbal supplements — most have never been rigorously tested in pregnancy, because conducting such trials raises significant ethical and practical challenges. But the absence of evidence is not evidence of absence, and it is not evidence of safety.

What Traditional Ayurvedic Medicine Actually Says

This is a point frequently glossed over in popular wellness content: traditional Ayurvedic medicine did not universally endorse ashwagandha during pregnancy. Certain Ayurvedic texts specifically cautioned against high-dose use in early pregnancy due to potential emmenagogue (menstruation-inducing) and abortifacient properties. The same alkaloid compounds that give ashwagandha its adaptogenic properties may stimulate uterine contractions at sufficient doses.

This traditional caution is one reason that modern regulatory bodies have not simply waved ashwagandha through as "safe because it's ancient." The historical record cuts both ways.

Animal Data: Reassuring But Limited in Applicability

A 2025 study published in Frontiers in Pharmacology conducted a comprehensive reproductive and developmental safety assessment of a standardized ashwagandha root extract in Wistar rats. The findings were broadly reassuring: the researchers reported no evidence of toxicity across development and reproduction, with no significant effects on body weight, reproductive organ weight, or serum T4/TSH levels, and no histopathological toxicity in examined tissues.

The same study found that the standardized root extract did not induce reproductive or developmental toxicity and referenced a NOAEL (No Observed Adverse Effect Level) of 2,000 mg/kg body weight per day from prior repeated-dose rat work. For context, typical human supplemental doses of ashwagandha range from 300–600 mg/day — a small fraction of the rat NOAEL even after allometric scaling adjustments.

However, animal-to-human extrapolation has well-known limitations. Rats metabolize compounds differently than humans, gestation length and fetal development timelines differ substantially, and the specific ashwagandha formulation tested may not match what is on store shelves. Animal reproductive safety data is a necessary but not sufficient basis for recommending supplement use in human pregnancy.

4. The 2026 Human Clinical Study: A Closer Look

Study Design and Population

The most significant new piece of evidence in this debate is a 2026 prospective, randomized, comparative, open-label, 12-week study published in Frontiers in Global Women's Health under the title "Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Pregnant Women."

This study enrolled 70 healthy pregnant women and assessed the safety and efficacy of a standardized ashwagandha root extract over 12 weeks of intervention. This is the most direct human evidence we have on ashwagandha pregnancy safety as of 2026.

Safety Findings

The safety results from this trial are genuinely encouraging:

• No adverse events were reported during the study period
• No serious adverse events occurred in any participant
• Laboratory assessments showed no detrimental effects on hepatic (liver) function
• No detrimental effects on renal (kidney) function were detected
• No detrimental effects on thyroid function were observed

These findings are significant. Concerns about ashwagandha's impact on liver function have emerged in general population case reports (hepatotoxicity has been documented in non-pregnant adults), and the potential for thyroid disruption is a recognized concern given ashwagandha's known thyroid-modulating properties. The fact that a 12-week clinical trial in 70 pregnant women showed no detrimental effects on any of these systems is meaningful data.

Efficacy Findings

Beyond safety, the study reported several positive efficacy outcomes that directly address common pregnancy concerns:

• Improved hemoglobin levels — clinically relevant given the high prevalence of pregnancy-related anemia
• Improved red blood cell (RBC) quality — supporting better oxygen transport to the fetus
• Reduced perceived stress — measured via validated psychometric instruments
• Multiple aspects of sleep improvement — including sleep onset, duration, and quality metrics

These are not trivial outcomes. Anemia, stress, and sleep disruption are among the most clinically significant modifiable concerns in pregnancy, with downstream effects on both maternal and fetal wellbeing.

Important Limitations to Acknowledge

Despite these encouraging findings, the study has meaningful limitations that prevent it from being the final word on ashwagandha pregnancy safety:

1. Sample size (n=70): Statistically too small to detect rare adverse events. A serious adverse event occurring in 1 in 500 women would likely not appear in a 70-person trial.
2. Open-label design: Participants and researchers knew who was receiving the intervention, introducing potential bias in subjective outcome reporting.
3. 12-week duration: Pregnancy lasts approximately 40 weeks. Long-term effects through the third trimester and on neonatal outcomes are not captured.
4. Healthy participants only: The study enrolled healthy pregnant women. Findings cannot be automatically extrapolated to women with comorbidities, high-risk pregnancies, or concurrent medication use.
5. Formulation specificity: Results are tied to the specific standardized extract tested. Other ashwagandha products may have different phytochemical profiles.
6. Lack of placebo control: Without a blinded placebo arm, it is difficult to separate true drug effects from expectation effects, especially for subjective outcomes like stress and sleep.

The authors of the study and independent reviewers have acknowledged these limitations. The study is best understood as promising preliminary evidence that warrants larger, more rigorous follow-up research — not as definitive proof of safety for broad population use.

★★★★★ 4.8 · 1,247 reviews

The Adaptogens Your Nervous System Has Been Missing.

Ashwagandha, rhodiola, and phosphatidylserine — clinically-studied ingredients that support healthy cortisol rhythms.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

5. Risk Concerns: Miscarriage, Premature Delivery, and Fetal Harm

The Miscarriage Question

One of the most frequently asked questions about ashwagandha pregnancy safety is whether it increases the risk of miscarriage. This concern originates from multiple sources:

Pharmacological plausibility: Withanolides and alkaloids in ashwagandha have demonstrated uterotonic (uterine muscle-stimulating) properties in some in vitro (cell culture) and animal studies. Compounds that stimulate uterine smooth muscle can theoretically increase miscarriage risk, particularly in the first trimester when the embryo is most vulnerable.

Traditional texts: As noted above, some Ayurvedic sources classified ashwagandha as having emmenagogue properties — meaning it could stimulate menstrual flow — which, in a pregnant woman, could translate to pregnancy loss risk.

Case reports and registry data: There are documented case reports associating ashwagandha use with adverse pregnancy outcomes, though case reports cannot establish causation and are subject to significant reporting biases.

Expert consensus summaries: The Consensus.app review of existing pregnancy research explicitly lists miscarriage and premature delivery as potential risk concerns warranting caution.

It is critical to note that the 2026 human trial did not report miscarriages in its cohort — but at n=70, this is insufficient to rule out a small increased risk that would only become apparent in larger studies.

Premature Delivery Risk

Similar pharmacological reasoning applies to premature delivery risk. Uterotonic compounds have the potential to stimulate contractions at any gestational age. While the 2026 trial did not report premature deliveries, the sample size and study design cannot adequately address this concern.

Potential for Fetal Harm

Beyond direct uterine effects, theoretical mechanisms for fetal harm include:

• Hormonal disruption: Ashwagandha modulates cortisol, DHEA, thyroid hormones, and potentially sex steroids. Fetal development is acutely sensitive to hormonal milieu, and disruption of maternal hormone levels could affect organogenesis and neurodevelopment.
• Placental transfer: Many withanolide compounds are lipophilic (fat-soluble), raising the possibility of placental transfer and direct fetal exposure. This has not been well-characterized in human studies.
• Withanolide immunomodulatory effects: Ashwagandha's immune-modulating properties are central to its adaptogenic mechanism. The maternal immune system undergoes specific and carefully calibrated changes during pregnancy (tolerance of the semi-allogeneic fetus requires immunological modulation). Whether ashwagandha's immune effects interfere with these pregnancy-specific immune adaptations is unknown.

None of these mechanisms have been definitively demonstrated to cause harm in human pregnancy — but none have been ruled out either. The precautionary principle argues for caution in the absence of stronger reassurance data.

6. Ashwagandha Lactation: Is It Safe While Breastfeeding?

The Evidence Gap Is Even Larger

If the human evidence on ashwagandha during pregnancy is limited, the evidence on ashwagandha lactation safety is essentially nonexistent at a clinical level.

InfantRisk, one of the most respected resources on medication and supplement safety during breastfeeding, notes an absence of substantial evidence on ashwagandha transfer into breast milk and limited understanding due to the lack of standardized reporting for herbal exposures in breastfeeding populations. This is not a minor qualification — it means we have no reliable data on:

• Whether ashwagandha compounds (withanolides, alkaloids, saponins) pass into human breast milk
• What concentrations of these compounds an infant might receive through breast milk
• Whether those concentrations are pharmacologically significant in a newborn or infant
• Whether infant exposure affects development, organ function, hormone levels, or other outcomes

Why Infant Exposure Is a Particular Concern

Newborns and infants metabolize compounds very differently from adults and even from pregnant women. Neonatal liver enzyme systems (particularly cytochrome P450 enzymes involved in drug and xenobiotic metabolism) are immature at birth and develop progressively over the first year of life. A compound that an adult metabolizes and excretes efficiently might accumulate to higher blood levels in a breastfed infant.

Additionally, infants are in a period of extraordinarily rapid neurological, hormonal, and immune development. Compounds that modulate cortisol, thyroid hormones, or immune function — all of which ashwagandha is known to influence in adults — could theoretically have disproportionate effects on developing systems in an infant.

Traditional Use Does Not Clarify the Picture

Ashwagandha has been used in traditional Ayurvedic postpartum tonics, which is sometimes cited as evidence of lactation safety. However, traditional preparations often involved different plant parts, different preparation methods, and much lower standardized concentrations than modern supplements. Extrapolating from traditional postpartum tonic use to modern high-standardization ashwagandha capsules is not scientifically valid.

Regulatory and Clinical Guidance

The BfR (German Federal Institute for Risk Assessment) explicitly states in its ashwagandha risk assessment that there is a lack of safety data for breastfeeding mothers and advises this group not to use ashwagandha supplements. This is one of the clearest, most direct regulatory statements available on this topic.

Most clinical herbalists, integrative medicine practitioners, and obstetric pharmacologists who have reviewed the available evidence arrive at the same conclusion: the absence of safety data, combined with theoretical concerns about infant exposure, warrants avoidance during breastfeeding until better evidence emerges.

7. Ashwagandha Contraindications Beyond Pregnancy

Understanding the full picture of ashwagandha contraindications matters even outside of pregnancy and lactation. Several of these contraindications may be particularly relevant for women of reproductive age and for postpartum individuals who are not breastfeeding but have specific health conditions.

Documented and Likely Contraindications

1. Pregnancy (Discussed Above) The most evidence-supported contraindication, backed by regulatory guidance from multiple countries and the precautionary principle.

2. Breastfeeding (Discussed Above) Lack of safety data plus theoretical infant risk supports avoidance.

3. Active Autoimmune Disease Ashwagandha is an immunomodulator that generally appears to enhance immune function and Th1 immune responses. For individuals with autoimmune conditions — including lupus (SLE), rheumatoid arthritis, multiple sclerosis, Hashimoto's thyroiditis, inflammatory bowel disease, and others — this immune stimulation could theoretically exacerbate disease activity. This ashwagandha autoimmune caution is discussed in more detail in its own section below.

4. Thyroid Disorders Ashwagandha has demonstrated the ability to increase thyroid hormone levels (T3 and T4) in multiple studies. For individuals with hyperthyroidism (overactive thyroid) or those on thyroid hormone replacement therapy, this could result in clinically significant hormone level changes.

5. Hormone-Sensitive Conditions Because ashwagandha may influence sex steroid hormone levels (testosterone, DHEA, estrogen), individuals with hormone-sensitive cancers (breast cancer, ovarian cancer, uterine cancer, prostate cancer) should use it only under direct medical supervision, if at all.

6. Upcoming Surgery Ashwagandha may have mild sedative properties, potentiate anesthesia, and affect central nervous system function. Most clinical guidelines recommend discontinuing herbal supplements 2–4 weeks before elective surgery.

7. Nightshade Allergy Since ashwagandha belongs to the Solanaceae (nightshade) family, individuals with known nightshade allergy or sensitivity should exercise caution or avoid it entirely.

8. Liver Disease or Compromised Hepatic Function While rare, hepatotoxicity cases associated with ashwagandha have been documented in case reports, including cases requiring liver transplantation. Individuals with pre-existing liver disease should avoid ashwagandha or use it only under close medical monitoring.

8. Ashwagandha Drug Interactions You Need to Know

Ashwagandha drug interactions are an important but frequently underemphasized aspect of its safety profile. Because ashwagandha is sold as a supplement rather than a pharmaceutical drug, many patients and even some clinicians may assume that interaction risks are minimal. This assumption is incorrect.

Sedatives and CNS Depressants

Ashwagandha has demonstrated sedative effects in both animal and human studies, likely mediated through GABAergic mechanisms (similar to the mechanism of benzodiazepines). When combined with:

• Benzodiazepines (alprazolam, lorazepam, diazepam)
• Z-drugs (zolpidem, eszopiclone)
• Barbiturates
• Opioid analgesics
• Antihistamines with sedative properties
• Alcohol

…the combined sedative effect may be significantly greater than either substance alone, increasing risk of excessive sedation, respiratory depression, and impaired cognitive function.

Thyroid Medications

Given ashwagandha's demonstrated capacity to elevate T3 and T4 levels, combining it with levothyroxine (Synthroid) or other thyroid hormone preparations could result in hyperthyroid-like symptoms (palpitations, anxiety, insomnia, weight loss, tremor). Regular thyroid function monitoring is essential if ashwagandha is used alongside thyroid medications.

Immunosuppressant Medications

Because ashwagandha stimulates immune function, it may directly oppose the mechanisms of medications intended to suppress the immune system, including:

• Corticosteroids (prednisone, methylprednisolone)
• Calcineurin inhibitors (cyclosporine, tacrolimus)
• Biologic agents (TNF inhibitors, IL-6 inhibitors)
• Antimetabolites (methotrexate, azathioprine)

This interaction is clinically significant for organ transplant recipients and individuals with autoimmune diseases managed with immunosuppressive therapy.

Antidiabetic Medications

Ashwagandha has demonstrated blood glucose-lowering effects in clinical studies. When combined with insulin or oral hypoglycemic agents (metformin, sulfonylureas, GLP-1 agonists), the additive glucose-lowering effect could cause hypoglycemia (dangerously low blood sugar).

Antihypertensive Medications

Some evidence suggests ashwagandha may lower blood pressure through multiple mechanisms. Combined with antihypertensive medications, this could produce additive blood pressure reduction and symptomatic hypotension.

CYP450 Enzyme Interactions

Preliminary evidence suggests ashwagandha may affect cytochrome P450 enzyme activity (particularly CYP2D6 and CYP3A4), which are responsible for metabolizing a wide range of pharmaceutical drugs. The clinical significance of these interactions is not yet well-characterized but represents a theoretical concern for individuals on multiple medications.

★★★★★ 4.8 · 1,247 reviews

See Why Athletes And Executives Take It Daily.

Adaptogen-based formula, third-party tested, made in the USA. Cancel subscription anytime.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

9. Ashwagandha Thyroid Interaction: Special Considerations

The ashwagandha thyroid interaction deserves its own dedicated section because it is both scientifically interesting and clinically important — particularly for pregnant and postpartum women, among whom thyroid disorders are relatively common.

How Ashwagandha Affects Thyroid Hormones

Multiple clinical studies have demonstrated that ashwagandha supplementation can significantly increase serum levels of T3 (triiodothyronine) and T4 (thyroxine) while simultaneously decreasing TSH (thyroid-stimulating hormone). This pattern is consistent with enhanced thyroid hormone production and/or improved conversion of T4 to the more active T3.

A 2019 double-blind, randomized, placebo-controlled trial published in Medicine found significant increases in T3 and T4 alongside decreased TSH in subjects receiving ashwagandha root extract compared to placebo over 8 weeks. These changes were statistically significant even in individuals who were not thyroid-deficient at baseline.

Implications for Hypothyroidism

For individuals with subclinical or overt hypothyroidism who are seeking complementary support, these findings might seem encouraging. Some integrative medicine practitioners have explored ashwagandha as an adjunct support for hypothyroid patients. However, several cautions apply:

• The magnitude of thyroid hormone elevation varies significantly between individuals and studies
• Combining ashwagandha with levothyroxine creates risk of over-treatment and hyperthyroid symptoms
• Thyroid hormone levels during pregnancy require precise management; even modest fluctuations can affect fetal neurodevelopment
• Postpartum thyroiditis affects approximately 5–10% of women; ashwagandha's thyroid-modulating effects could complicate its natural course

The 2026 Clinical Trial: No Adverse Thyroid Effects

Importantly, the 2026 Frontiers in Global Women's Health study found no detrimental effects on thyroid function in pregnant women over 12 weeks. Similarly, the 2025 rat reproductive toxicity study found no significant effects on serum T4 or TSH at tested doses. These findings provide some reassurance that the standardized extract tested does not cause pathological thyroid disruption in the short term — but ongoing monitoring of thyroid function remains advisable for anyone using ashwagandha who has a known thyroid condition.

Implications for Hashimoto's Thyroiditis

Hashimoto's is an autoimmune thyroid condition and the most common cause of hypothyroidism. It involves the immune system attacking thyroid tissue. Ashwagandha's immune-stimulating properties create a theoretically concerning profile for Hashimoto's patients: enhanced immune activity could potentially amplify the autoimmune attack on thyroid tissue. This makes Hashimoto's a situation where both the ashwagandha thyroid interaction and the ashwagandha autoimmune caution apply simultaneously.

10. Ashwagandha Autoimmune Caution

The ashwagandha autoimmune caution is one of the most important and frequently overlooked aspects of its safety profile. This concern arises directly from ashwagandha's most celebrated pharmacological property: its ability to modulate immune function.

How Ashwagandha Modulates Immunity

Ashwagandha has been shown in multiple studies to:

• Increase natural killer (NK) cell activity
• Enhance lymphocyte proliferation
• Upregulate Th1 cytokine responses (including IFN-γ, IL-2, and TNF-α)
• Modulate macrophage activity
• Affect immunoglobulin production

In a healthy individual with a suppressed or poorly regulated immune system (such as someone recovering from illness or under chronic stress), these immune-enhancing effects may be beneficial. However, in an individual whose immune system is already overactive — specifically targeting the body's own tissues — immune enhancement can be profoundly counterproductive.

Conditions Warranting Specific Caution

Systemic Lupus Erythematosus (SLE): SLE is driven by dysregulated immune activation and elevated Th1/Th17 responses. Immune-stimulating supplements, including ashwagandha, could theoretically trigger or worsen flares.

Rheumatoid Arthritis (RA): While some anti-inflammatory effects of ashwagandha have been documented, its immune-stimulating properties could complicate the management of RA, particularly in patients on biologic therapies.

Multiple Sclerosis (MS): MS involves autoimmune attack on myelin in the central nervous system. Immune stimulation could potentially accelerate disease activity, though clinical data specifically in MS patients is lacking.

Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis): IBD management increasingly recognizes the complexity of mucosal immune regulation. Broad immune stimulation could affect disease course unpredictably.

Psoriasis and Psoriatic Arthritis: These conditions involve dysregulated Th17 immune responses. Ashwagandha's immunomodulatory effects could theoretically affect disease activity.

The Pregnancy-Autoimmune Overlap

Some pregnant women have pre-existing autoimmune conditions and may be managing them with immunosuppressive medications during pregnancy. In this population, the ashwagandha autoimmune caution intersects with pregnancy contraindications, potential drug interactions with immunosuppressants, and the specific immunological requirements of pregnancy itself — creating a particularly complex risk calculus that should only be navigated with direct specialist guidance.

11. Who Should Not Take Ashwagandha?

Synthesizing the evidence and ashwagandha contraindications reviewed throughout this post, here is a clear summary of who should not take ashwagandha or should only do so under close medical supervision:

Clear Avoidance Recommended

| Population | Primary Reason | |---|---| | Pregnant women | Risk of miscarriage, premature delivery, fetal harm; insufficient safety data | | Breastfeeding women | Absence of infant safety data; potential for infant exposure via breast milk | | Children and adolescents | Lack of pediatric safety data; potential hormonal effects during development | | Individuals with active autoimmune disease | Risk of immune stimulation worsening autoimmune activity | | Individuals with hyperthyroidism or Graves' disease | Risk of further elevating already-high thyroid hormone levels | | Pre-surgical patients (2-4 weeks before surgery) | Sedative effects, potential anesthesia interaction | | Individuals with known nightshade allergy | Allergen cross-reactivity risk | | Individuals with active liver disease or hepatic impairment | Documented hepatotoxicity risk in case reports |

Use Only Under Medical Supervision

| Population | Primary Reason | |---|---| | Individuals on thyroid hormone replacement (levothyroxine) | Risk of additive thyroid hormone elevation | | Individuals on immunosuppressant medications | Risk of opposing immunosuppressant mechanism | | Individuals on antidiabetic medications | Risk of additive hypoglycemia | | Individuals on antihypertensive medications | Risk of additive blood pressure reduction | | Individuals on CNS depressants or sedatives | Risk of additive sedation | | Individuals with hormone-sensitive cancers | Potential hormonal modulation effects | | Individuals with subclinical hypothyroidism | Thyroid modulation may require dose adjustment of medications | | Individuals on multiple pharmaceutical medications | Potential CYP450 enzyme interactions |

12. What Regulators Say: A Global Ashwagandha Safety Review

This ashwagandha safety review section compiles the positions of major regulatory and scientific bodies as of 2026.

Germany: BfR (Federal Institute for Risk Assessment)

The BfR, Germany's Federal Institute for Risk Assessment, published a formal risk assessment of ashwagandha in food supplements that represents one of the most rigorous governmental evaluations available. Their conclusions are unambiguous:

• There is a lack of safety data for pregnant women, breastfeeding mothers, and children
• These groups are specifically advised not to use ashwagandha supplements
• The BfR flagged concerns about hepatotoxicity, thyroid interaction, and drug interactions
• The report called for more standardized research before safety claims can be made for general population use

This assessment carries significant regulatory weight and has influenced how ashwagandha supplements are labeled in multiple European markets.

Consensus.app Systematic Review Summary

The Consensus.app AI-synthesized summary of ashwagandha pregnancy research — drawing on multiple published studies — reinforces several key points:

• There is a lack of large-scale, well-designed randomized, double-blind, placebo-controlled trials in pregnant women
• Concerns about miscarriage, premature delivery, and fetal harm are noted as unresolved
• The evidence base is insufficient to support recommendations for use in pregnancy

United States: FDA and Regulatory Landscape

The U.S. Food and Drug Administration (FDA) regulates ashwagandha as a dietary supplement under DSHEA (Dietary Supplement Health and Education Act of 1994). Under this framework, manufacturers are not required to prove safety before marketing — the burden falls on the FDA to demonstrate harm. As a result, there is no formal FDA prohibition on ashwagandha use in pregnancy, but the FDA has not issued any positive safety determination either.

The American College of Obstetricians and Gynecologists (ACOG) advises pregnant women to consult their healthcare provider before using any herbal supplement, citing the general lack of rigorous safety data for botanical preparations in pregnancy.

InfantRisk Center

The InfantRisk Center at Texas Tech University Health Sciences Center, one of the world's leading resources on medication and supplement safety in breastfeeding, notes the absence of substantial evidence on ashwagandha during lactation. Without pharmacokinetic data on breast milk transfer and without infant outcome data, no safety determination can be made.

Healthline and Clinical Review Media

Healthline's coverage of ashwagandha in pregnancy, which consistently ranks among the top search results on this topic, reflects the current evidence-based consensus: the available data is insufficient to confirm safety, traditional use and some animal studies suggest theoretical risk, and avoidance during pregnancy and breastfeeding is the most defensible recommendation pending better evidence.

The Emerging Picture from 2024–2026 Research

The 2026 human trial in Frontiers in Global Women's Health and the 2025 animal reproductive toxicity study in Frontiers in Pharmacology collectively represent meaningful progress. They suggest that a specific standardized ashwagandha root extract, at studied doses, did not cause detectable harm in either a rat reproductive toxicity model or a 70-person open-label human trial. This is not nothing — it shifts the probability distribution slightly toward safety compared to a pure theoretical risk analysis.

However, these studies have not changed the positions of major regulatory bodies, which appropriately wait for larger, more rigorous, placebo-controlled human trials before revising safety guidance. That evidence does not yet exist.

★★★★★ 4.8 · 1,247 reviews

Ready To Try Adaptogen-Based Cortisol Support?

Third-party tested. 60-day guarantee. Free shipping over $40. Ships in 24 hours.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

13. Ashwagandha Safety Cautions: Practical Summary for Readers

Understanding ashwagandha safety cautions at a practical level helps translate the research discussion into actionable guidance. Here is a structured practical summary:

If You Are Pregnant

Current recommendation: Avoid ashwagandha.

While the 2026 clinical trial offers some reassurance, it involved only 70 healthy pregnant women over 12 weeks and lacked a placebo control. This is insufficient evidence to override the precautionary recommendations of the BfR and the absence of data on rare but serious outcomes like miscarriage and premature delivery. The potential theoretical risks — uterotonic effects, hormonal disruption, placental transfer of bioactive compounds — have not been definitively ruled out.

If you are currently taking ashwagandha and discover you are pregnant, do not panic — but do discuss with your obstetric provider promptly.

If You Are Breastfeeding

Current recommendation: Avoid ashwagandha.

No breast milk transfer data exists. No infant exposure safety data exists. Infants, especially newborns, have immature metabolic systems that may not handle ashwagandha's bioactive compounds the way an adult body would. Until this gap is filled by rigorous pharmacokinetic and safety research, avoidance is the most defensible approach.

If You Have a Thyroid Condition

Discuss with your endocrinologist or healthcare provider before use.

Ashwagandha's documented thyroid-elevating effects could be beneficial in some hypothyroid scenarios but harmful in hyperthyroid states or in individuals on precisely calibrated thyroid hormone replacement. Thyroid function should be monitored if use is initiated.

If You Have an Autoimmune Condition

Discuss with your rheumatologist, neurologist, or specialist before use.

The theoretical risk of immune exacerbation is not trivial. Your specialist will be able to weigh ashwagandha's pharmacological profile against your specific disease activity and treatment regimen.

If You Are on Prescription Medications

Disclose all supplement use to your prescribing physician.

The ashwagandha drug interactions discussed above — particularly with sedatives, thyroid medications, immunosuppressants, and antidiabetics — can be clinically significant. Your pharmacist is also an excellent resource for checking interaction potential.

If You Are a Healthy, Non-Pregnant Adult

The risk profile for healthy adults with no contraindicated conditions and no interacting medications is considerably more favorable. Most clinical trials in general populations have shown good short-term tolerability at standard doses (300–600 mg/day of standardized root extract). However, long-term safety data (beyond 12 weeks) remains limited, and the rare but documented risk of hepatotoxicity means that any unexplained gastrointestinal symptoms, fatigue, jaundice, or dark urine during ashwagandha use should prompt immediate cessation and medical evaluation.

14. Frequently Asked Questions

Is ashwagandha safe during pregnancy?

The honest answer is that we do not have sufficient evidence to confirm safety. The most recent human clinical trial (2026, n=70) did not detect adverse events over 12 weeks, and the most recent animal reproductive toxicity study (2025) found no reproductive or developmental toxicity in rats. However, major regulatory bodies including Germany's BfR continue to advise against use during pregnancy due to insufficient safety data and theoretical concerns about miscarriage, premature delivery, and fetal harm. Most obstetric healthcare providers recommend avoiding ashwagandha during pregnancy pending larger, more rigorous human trials.

Can ashwagandha cause miscarriage?

There is no definitive clinical proof that ashwagandha causes miscarriage in humans. However, some of ashwagandha's pharmacological constituents (particularly certain alkaloids) have demonstrated uterotonic properties in laboratory and animal studies. Traditional Ayurvedic medicine included cautions about ashwagandha in early pregnancy based on these properties. The existing human evidence base is too small to detect a modest increase in miscarriage risk. Precautionary avoidance is warranted.

Is ashwagandha safe while breastfeeding?

Insufficient evidence exists to confirm safety during breastfeeding. No human pharmacokinetic data on breast milk transfer is available, and no infant safety studies have been conducted. InfantRisk notes the absence of substantial evidence, and the BfR specifically advises breastfeeding women not to use ashwagandha supplements. Avoidance is recommended.

Does ashwagandha pass into breast milk?

This has not been studied in humans. Ashwagandha contains multiple lipophilic compounds (withanolides) that theoretically could cross into breast milk, but without direct measurement data, the actual concentration that might reach a nursing infant is unknown.

What do the 2024–2026 studies say about ashwagandha in pregnancy?

The two most recent high-quality studies are: (1) a 2026 randomized open-label human trial in 70 healthy pregnant women showing no adverse events and improved hemoglobin, stress, and sleep outcomes over 12 weeks; and (2) a 2025 rat reproductive and developmental toxicity study showing no evidence of toxicity at tested doses. These are encouraging preliminary findings, but both have significant limitations. Regulatory bodies have not revised their avoidance recommendations based on these studies.

What are the main ashwagandha contraindications?

The main ashwagandha contraindications include: pregnancy, breastfeeding, active autoimmune disease, hyperthyroidism, hormone-sensitive cancers, active liver disease, pre-surgical periods, and nightshade allergy. Use requires medical supervision in individuals taking thyroid medications, immunosuppressants, antidiabetics, antihypertensives, or CNS depressants.

Does ashwagandha interact with thyroid medication?

Yes — this is one of the most clinically significant ashwagandha drug interactions. Ashwagandha raises T3 and T4 levels. When combined with levothyroxine or other thyroid hormones, this could result in hyperthyroid symptoms. Thyroid function monitoring is essential if both are used simultaneously, and most clinicians would advise against combining them without specialist guidance.

Who should not take ashwagandha?

Pregnant women, breastfeeding women, children, individuals with active autoimmune disease, those with hyperthyroidism, pre-surgical patients, individuals with nightshade allergy, and those with active liver disease should avoid ashwagandha. Individuals on multiple prescription medications should consult their healthcare provider before use.

15. Bottom Line

The question of ashwagandha safety in pregnancy and lactation sits at an unusual intersection of ancient tradition, rapidly growing research, aggressive commercial marketing, and genuine evidence gaps — all playing out in a context where the stakes could not be higher: the health of pregnant and nursing mothers and their infants.

Here is where the evidence actually stands in 2026:

The encouraging news: A 2026 human clinical trial in 70 pregnant women reported no adverse events and improved hemoglobin, stress, and sleep outcomes with standardized ashwagandha root extract over 12 weeks. A 2025 rat reproductive toxicity study found no evidence of reproductive or developmental harm. These are meaningful positive data points that did not exist five years ago.

The sobering reality: These studies are preliminary. The human trial was small, open-label, and of limited duration. Neither study can rule out rare but serious outcomes. Major regulatory bodies, including the German BfR, continue to advise pregnant and breastfeeding women to avoid ashwagandha due to insufficient safety data. The theoretical mechanisms for harm — uterotonic effects, hormonal disruption, infant exposure via breast milk — have not been definitively ruled out.

The practical guidance: The weight of current evidence supports avoiding ashwagandha during pregnancy and breastfeeding. For individuals in other populations, ashwagandha safety cautions around thyroid conditions, autoimmune disease, and drug interactions warrant careful consideration and medical disclosure. For healthy adults without contraindications, short-term use at standard doses is generally well-tolerated, but anyone experiencing unexplained liver-related symptoms should stop immediately and seek medical evaluation.

The good news for the future: the research pipeline is more active than it has ever been, and if the quality and scale of human trials continues to improve, we may have considerably clearer answers about ashwagandha pregnancy safety and lactation within the next several years. Until then, caution — not fear, but evidence-informed caution — is the appropriate posture.

If you found this article helpful, consider sharing it with others who may be weighing ashwagandha use during pregnancy or breastfeeding. For personalized medical guidance, always consult a qualified healthcare provider.

References and Sources:

1. Consensus.app. Ashwagandha Use During Pregnancy — Evidence Summary. consensus.app/questions/ashwagandha-use-during-pregnancy/
2. Healthline. Ashwagandha and Pregnancy. healthline.com/health/pregnancy/ashwagandha-pregnancy
3. Kulkarni R, et al. Efficacy and safety of Ashwagandha (Withania somnifera) root extract in pregnant women: a prospective, randomized, comparative, open-label, 12-week study. Frontiers in Global Women's Health. 2026.
4. Murthy SR, et al. Reproductive and developmental safety assessment of standardized Ashwagandha root extract. Frontiers in Pharmacology. 2025.
5. German Federal Institute for Risk Assessment (BfR). Ashwagandha — Food Supplements with Potential Health Risks. bfr.bund.de/cm/349/ashwagandha-food-supplements-with-potential-health-risks.pdf
6. InfantRisk Center, Texas Tech University Health Sciences Center. Herbal Supplement Safety in Lactation.

This post was last reviewed and updated in 2026. Evidence summaries reflect peer-reviewed literature available at time of publication.